EUCTR2006-001956-11-BE进行中（未招募）不适用
Randomized Phase II Study of Amrubicin as Single Agent or in Combination with Cisplatin versus Etoposide-Cisplatin as first-Line Treatment in Patients with Extensive Stage SCLC
Celgene International SAR0 个研究点目标入组 97 人开始时间: 2006年7月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 97
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically/cytologically proven small cell lung cancer
- •Extensive disease as defined by Davis et al
- •WHO performance status 0-2
- •Measurable disease according to RECIST criteria (imaging within 28 days prior to entry)
- •Age = 18 years
- •Normal baseline cardiac function
- •No prior systemic chemotherapy for small cell lung cancer
- •No radiotherapy for SCLC within 14 days before treatment
- •Adequate haematological function (WBC >1.5 x 10^9 /L, platelets >100 x 10^9 /L, Hb> 9 g/dL)
- •Creatinine clearance: = 60ml/min (Cockroft and Gault)
- •Adequate hepatobiliary function (ALT/AST <2.5 x Upper Limit of Normal)
- •All the blood tests should be performed within 14 days of patient inclusion.
- •No history of interstitial lung disease or pulmonary fibrosis
- •No history of prior malignancy unless patient has been disease free for >5 years, or the tumour was a non-melanoma skin cancer or in-situ carcinoma of the cervix
- •Absence of uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, New York Heart Association Class III or IV heart failure, uncontrolled angina, clinical significant pericardial disease or cardiac amyloidosis.
- •Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- •No pregnancy or breast feeding. Men and Women of child bearing potential must use an appropriate method of contraception if the risk of conception exists
- •Written informed consent before randomization, according to ICH/EU GCP, and national/local regulations.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Randomized Phase II Study of Amrubicin as Single Agent or in Combination with Cisplatin versus Etoposide-Cisplatin as first-Line Treatment in Patients with Extensive Stage SCLCSmall Cell Lung Cancer (extensive stage)MedDRA version: 8.1Level: LLTClassification code 10041068Term: Small cell lung cancer extensive stageEUCTR2006-001956-11-NLCabrellis Pharmaceuticals Corporation85
进行中（未招募）
1 期
Randomized Phase II Study of Amrubicin as Single Agent or in Combination with Cisplatin versus Etoposide-Cisplatin as first-Line Treatment in Patients with Extensive Stage SCLCEUCTR2006-001956-11-GBCelgene International SAR97
进行中（未招募）
不适用
Randomized phase II study of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients with extensive stage SCLC ES - NDPatient with small cell lung cancer.MedDRA version: 6.1Level: PTClassification code 10041068EUCTR2006-001956-11-ITCABRELLIS PHARMACEUTICALS CORPORATIO85
尚未招募
2 期
Randomized phase II study of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients with extensive stage SCLC (ES).lung cancerNL-OMON30640European Organisation for Research in Treatment of Cancer (EORTC)14
已完成
2 期
A phase II study of amrubicin for previously treated small cell lung cancerFor patients with recurrent small cell lung cancerJPRN-UMIN000001752Gunma University Hospital35